Thermo Fisher Scientific (TMO) Wins Kapiglucagon Contract, Is The Stock Still Undervalued?
Thermo Fisher Scientific (TMO) is back in focus after ImmuPharma selected the company to develop and manufacture the finished drug product for its experimental diabetes treatment Kapiglucagon, following a competitive tender process.
See our latest analysis for Thermo Fisher Scientific.
The Kapiglucagon contract lands as Thermo Fisher Scientific’s recent share price has climbed, with a 30-day share price return of 13.46% and a 90-day gain of 12.80%. The year-to-date share price return is still down 11.15%, and the 1-year total shareholder return sits at 13.21%, pointing to improving momentum after a tougher stretch.
If this kind of contract win has you thinking about long term themes in healthcare and automation, it could be a good time to check out a focused list of 33 robotics and automation stocks
Thermo Fisher Scientific’s recent rebound and fresh contract win support a more positive view that the stock is regaining its footing, while skeptics point to longer term total returns that appear more muted. How does the valuation stack up now?
Most Popular Narrative: 10.9% Undervalued
At a last close of $526.46 versus a narrative fair value of about $590.77, Thermo Fisher Scientific screens as modestly undervalued, with the gap tied to expectations around earnings growth, margins and long term demand in life sciences tools.
Ongoing strategic M&A and capacity expansion (for example, Solventum acquisition), combined with resilient end-market exposure to pandemic preparedness, diagnostics, and emerging market healthcare investment, positions the company for compounding top-line gains and elevated returns on capital as secular demand trends accelerate.
Curious what sits behind that fair value for Thermo Fisher Scientific? The narrative leans on specific revenue growth, margin expansion and valuation multiple assumptions that could materially shift how you see the current share price.
Result: Fair Value of $590.77 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Thermo Fisher Scientific still faces questions around slower academic and government demand, and ongoing China and tariff pressures that could weigh on the bullish narrative.
Find out about the key risks to this Thermo Fisher Scientific narrative.
Another View: Thermo Fisher Scientific Through Earnings Multiples
While the fair value estimate suggests Thermo Fisher Scientific is trading about 15.3% below intrinsic value, the earnings multiple tells a more cautious story. The current P/E of 28.6x sits above a fair ratio of 27.1x, even though it is below the peer average of 40.8x and the Global Life Sciences industry at 38x. That mix of relative value support and a premium to the fair ratio raises a simple question: is the stock already pricing in much of the good news investors are hoping for?
For a closer look at how this earnings multiple tension could resolve over time, check the valuation breakdown and see what the numbers imply for risk and upside, See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With Thermo Fisher Scientific presenting a mix of support and caution, now is the time to review the figures yourself and decide how the balance of risks and rewards stacks up for your portfolio. You can start with 2 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Thermo Fisher Scientific?
If Thermo Fisher Scientific has sharpened your focus on quality and valuation, do not stop here. Broaden your watchlist now with targeted ideas that fit your style.
- Target reliable income by reviewing companies that show up as 7 dividend fortresses, so your cash flow goals stay front and center.
- Strengthen your downside protection by scanning for 82 resilient stocks with low risk scores, built to help you focus on resilience when markets get choppy.
- Get ahead of the crowd by checking a screener containing 20 high quality undiscovered gems that could sit off most investors’ radar today.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com